PMC

Kaplan-Meier Curves using log rank tests for the recurrence of bladder cancer in patients. (a) The recurrence of bladder cancer in XPF(−) group with different status of smoking (never smoked, <20 pack-years, 20-50 pack-years and>50 pack-years); (b) The recurrence of bladder cancer in XPC(−) group with different status of smoking; (c) The recurrence of bladder cancer in XPF(+) group with different status of smoking; (d) The recurrence of bladder cancer in XPC(+) group with different status of smoking; (e) The recurrence of bladder cancer in patients of XPF(−) with never smoked and XPF(−) with smoked more than 50 pack-years;(f) The recurrence of bladder cancer in patients of XPC(−) with never smoked and XPC(−) with smoked more than 50 pack-years;(g) The recurrence of bladder cancer in patients of XPF(+) with never smoked and XPF(+) with smoked more than 50 pack-years; (h) The recurrence of bladder cancer in patients of XPC(+) with never smoked and XPC(+) with smoked more than 50 pack-years.

Each histogram indicates the proportion of patients with the recurrence groups in each nodal stage. Linear-by-linear association chi-squared test was performed for examination a trend between recurrence groups and nodal stage (P<0.001).

The performance of anisotropy as a recurrence predictor was compared across the low (0–2), intermediate (3–5) and high (6–11) CAPRA-S ranges. (A) At the low CAPRA-S range, the probability of recurrence was 7.5% and anisotropy (AUC 0.66) predicted recurrence with 70% sensitivity and 75% specificity. (B) At the intermediate CAPRA-S range, the probability of recurrence was 31.1%. Anisotropy (AUC 0.79) identified recurrence with 71% sensitivity and 65% specificity. (C) At the high CAPRA-S range, the probability of recurrence was 64.3% and anisotropy (AUC 0.71) identified recurrence with 78% sensitivity and 80% specificity.

Kaplan‐Meier analysis of overall survival and postrecurrence survival. (A): Kaplan‐Meier analysis of overall survival in patients without recurrence, patients with early recurrence, and patients with late recurrence after curative liver resection of hepatitis B virus–associated hepatocellular carcinoma: p < .001 (without recurrence vs. early recurrence), p < .001 (without recurrence vs. late recurrence), and p < .001 (early recurrence vs. late recurrence) (log‐rank test). (B): Kaplan‐Meier analysis of postrecurrence survival in patients with early and late recurrence after curative liver resection of hepatitis B virus–associated hepatocellular carcinoma: p < .001 (log‐rank test).